GW Medical Technologies LLC
This article was originally published in Start Up
Executive Summary
GW Medical Technologies' blood test for Alzheimer's is one of the few that doesn't attempt to directly measure amyloid beta. Instead, the company's diagnostic measures CD69 levels on peripheral blood lymphocytes. Two clinical trials of the test, developed at the University of Leipzig, have already been performed and the data suggest the diagnostic is 95% accurate.
You may also be interested in...
RCP Diagnostics LLC
The principal goal of RCP Diagnostics is to commercialize a blood-based diagnostic for estrogen-associated cancers in women. The assay, initially developed as a radioimmunoassay, detects the presence of a protein that ferries vitamin B-2, or riboflavin, throughout the body.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.